A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anaemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Trial Profile

A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anaemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Mar 2018

At a glance

  • Drugs Epoetin alfa (Primary)
  • Indications Chemotherapy-induced anaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 05 Feb 2018 Status changed from active, no longer recruiting to completed.
    • 09 Dec 2017 Results of final analysis of overall survival (at 1653 deaths) and updated progression-free survival data, presented at the 40th Annual San Antonio Breast Cancer Symposium.
    • 01 Mar 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top